Results 61 to 70 of about 2,667 (188)

Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy. [PDF]

, 2021
Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a life-threatening syndrome that occurs in adult and pediatric patients after hematopoietic stem cell transplantation.
Daha, Mohamed, Dudler, Thomas, Fujita, Teizo, Gavriilaki, Eleni, Ho, Vincent T, Jodele, Sonata, Schwaeble, Wilhelm   +6 more
core   +2 more sources

Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis

Annals of Clinical and Translational Neurology
Objective Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy and tolerability for patients with anti‐acetylcholine receptor‐positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials and subsequent ...
Daiki Tokuyasu, Shigeaki Suzuki, Akiyuki Uzawa, Yuriko Nagane, Masayuki Masuda, Shingo Konno, Tomoya Kubota, Makoto Samukawa, Takamichi Sugimoto, Kei Ishizuchi, Munenori Oyama, Manato Yasuda, Hiroyuki Akamine, Yosuke Onishi, Yasushi Suzuki, Naoki Kawaguchi, Naoya Minami, Takashi Kimura, Masanori P. Takahashi, Hiroyuki Murai, Kimiaki Utsugisawa   +20 more
doaj   +1 more source

Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study [PDF]

INTRODUCTION/AIMS: The CHAMPION MG study demonstrated that ravulizumab significantly improved Myasthenia Gravis-Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) total scores versus placebo in adults with acetylcholine receptor
Beasley, Kathleen N., CHAMPION MG Study Group, Howard, James F., Kushlaf, Hani, Liao, Serena, Mantegazza, Renato, Meisel, Andreas, Suzuki, Shigeaki, Vu, Tuan, Wiendl, Heinz   +9 more
core   +2 more sources

Efficacy and Safety of Rituximab Versus Inebilizumab in Patients With Neuromyelitis Optica Spectrum Disorder: A Dual‐Center, Real‐World Cohort Study

European Journal of Neurology, Volume 33, Issue 3, March 2026.
In our real‐world study of 276 patients, rituximab and inebilizumab demonstrated comparable efficacy in the medium term but differed in their safety profiles, with a significantly higher incidence of infusion‐related reactions observed in the rituximab group.
Ying Cui, Zihao Yu, Hengri Cong, Hao Zhang, Yutong Shi, Ai Guo, Yujing Li, Dongmei Jia, Chao Zhang, Kaibin Shi, Fu‐Dong Shi, Wei Jiang   +11 more
wiley   +1 more source

Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience [PDF]

Introduction: Ravulizumab, a monoclonal antibody targeting C5, was recently approved for the treatment of anti-AChR positive generalized myasthenia gravis (gMG) patients.
Falso, Silvia, Iorio, Raffaele, Marini, Sofia   +2 more
core   +1 more source

Acute respiratory distress syndrome: potential of therapeutic interventions effective in treating progression from COVID-19 to treat progression from other illnesses—a systematic review [PDF]

, 2023
Background: Acute respiratory distress syndrome (ARDS) is the most severe form of lung injury, rendering gaseous exchange insufficient, leading to respiratory failure.
Campbell, Richard a, Harris, Lynda k, Ragel, Emma j   +2 more
core   +1 more source

Minimal Symptom Expression in Generalized Myasthenia Gravis: A Valuable Patient‐Centric Treatment Goal

European Journal of Neurology, Volume 33, Issue 3, March 2026.
Conceptual framework supporting Minimal Symptom Expression (MSE) as a patient‐centric treatment goal in generalized myasthenia gravis. Guidelines prioritize minimal manifestations (MM) or better (MGFA‐PIS); MM is clinician‐judgment based and not instrument‐defined. MSE (MG‐ADL 0‐1) is standardized, actionable, and widely used. Across Phase III programs
Andreas Meisel, Akiyuki Uzawa, Cynthia Z. Qi, Dustin Nowacek, Jeff Guptill, James F. Howard Jr   +5 more
wiley   +1 more source

Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials

Kidney Medicine
Rationale & Objective: Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by complement dysregulation. Ravulizumab is a C5i approved for the treatment of aHUS. This analysis assessed long-term outcomes
Bradley P. Dixon, David Kavanagh, Alvaro Domingo Madrid Aris, Brigitte Adams, Hee Gyung Kang, Edward Wang, Katherine Garlo, Masayo Ogawa, Praveen Amancha, Sourish Chakravarty, Nils Heyne, Seong Heon Kim, Spero Cataland, Sung-Soo Yoon, Yoshitaka Miyakawa, Yosu Luque, Melissa Muff-Luett, Kazuki Tanaka, Larry A. Greenbaum   +18 more
doaj   +1 more source

Meningococcal Serogroup Y Meningitis Reveals Inborn Factor B Deficiency

European Journal of Immunology, Volume 56, Issue 2, February 2026.
We report a novel case of complete complement Factor B deficiency revealed by invasive meningococcal disease. Using combined functional and genetic analyses, we demonstrate that loss of Factor B abolishes alternative pathway activity despite detectable protein levels. These findings provide a mechanistic framework relevant to complement diagnostics and
Camille Bougeard, Eléonore Eskander, Paula Vieira Martins, Joan Bitan, Julia Roquigny, Christèle Kyheng, Tamazoust Guiddir, Véronique Frémeaux‐Bacchi, Cécile Gonnin, Carine ElSissy   +9 more
wiley   +1 more source

The Complement System in ANCA‐Associated Vasculitis: Mechanistic Insights, Therapeutic Horizons, and Unmet Clinical Needs

Immunity, Inflammation and Disease, Volume 14, Issue 2, February 2026.
Complement activation, particularly via the alternative pathway, drives inflammation and organ damage in ANCA‐associated vasculitis. This review highlights mechanistic insights, tissue and biomarker evidence, and clinical implications of targeting the C5a–C5aR1 axis.
Kehinde Sunmboye, Pauline Millan
wiley   +1 more source